Babraham, AZ and Pfizer in Open Innovation Alliance
BusinessWeekly reports that three Cambridge UK biomed technology powerhouses have reaffirmed their commitment to the open innovation agenda through a new initiative at the heart of the Cambridge cluster. The new collaboration aims to identify new therapeutic treatments, with the premise that early-stage collaboration maximizes success. Babraham Research Campus, home to both the Babraham Institute and 35 early stage biomedical enterprises within its Bioincubator; Neusentis – a division of Pfizer; and MedImmune – the biologics arm of Astra Zeneca have joined forces.
Click here to read the full article.